Irritable Bowel Syndrome: Helping Patients Access Appropriate Treatment in an Era of Investigation and Discovery

,
Pharmacy Times, November 2015 Cough, Cold, & Flu, Volume 81, Issue 11

This Continuing Education activity is supported by an independent educational grant from Allergan Inc. and Prometheus Laboratories, Inc.

This activity is supported by an independent educational grant from Allergan Inc. and Prometheus Laboratories, Inc.

Irritable Bowel Syndrome: Helping Patients Access Appropriate Treatment in an Era of Investigation and Discovery

Faculty

Mary Barna Bridgeman, PharmD, BCPS,

CGP

Clinical Associate Professor

Department of Pharmacy Practice and Administration

Ernest Mario School of Pharmacy

Rutgers, The State University of New Jersey

Piscataway, New Jersey

Marc G. Sturgill, PharmD

Associate Professor and Chairman

Department of Pharmacy Practice and Administration

Ernest Mario School of Pharmacy

Rutgers, The State University of New Jersey

Piscataway, New Jersey

Educational Objectives

After completing this continuing education program, the participant will be able to:

  • Differentiate the clinical signs and symptoms of irritable bowel syndrome (IBS), including indicators of type and severity, and other conditions to rule out in a differential diagnosis.
  • Demonstrate knowledge of the appropriate indications, mechanisms of action, dosing, possible drug interactions, and major adverse effects of available and emerging IBS treatments.
  • Examine patients’ symptoms, medical status, disease severity, and possible contraindications to OTC treatment in patients with IBS.

Target audience: Pharmacists

Type of activity: Application

Release date: November 7, 2015

Expiration date: November 7, 2016

Estimated time to complete activity: 2.0 hours

Fee: Free

Pharmacy Times Office of Continuing Professional Education is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 2.0 contact hours (0.2 CEUs) under the ACPE universal activity number 0290-0000-15-142-H01-P. The activity is available for CE credit through November 7, 2016.